Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Eromycin
2. Erythromycin Propionate Dodecyl Sulfate
3. Erythromycin Propionate Lauryl Sulfate
4. Erythromycin Propionate Monododecyl Sulfate
5. Estolate, Erythromycin
6. Ilosone
7. Lauromicina
1. Ilosone
2. 3521-62-8
3. Lauromicina
4. Erythromycin Propionate Lauryl Sulfate
5. Marcoeritrex
6. Stellamicina
7. Eritroger
8. Estomicina
9. Roxomicina
10. Neo-erycinum
11. Erythromycin Estorate
12. Pels
13. Eromycin
14. Biomicron
15. Eriscel
16. Propionylerythromycin Lauryl Sulfate
17. Erythromycin (as Estolate)
18. Erythromycin 2'-propionate Dodecyl Sulfate (salt)
19. Xrj2p631hp
20. Erythromycin, 2'-propanoate, Dodecyl Sulfate (salt)
21. Prospiocine
22. Erytrarco
23. Lauryl Sulfate Propionyl Erythromycin Ester
24. Chebi:4846
25. Ery-toxinal Dodecylsulfate
26. Erythromycinestolate
27. Erythromycin Propionate, Compound With Dodecyl Sulfate
28. Nsc-263364
29. Lubomycine B
30. Erythromycin Estorate (jan)
31. Erythromycin Propionate Dodecylsulfate (salt)
32. Erythromycin 5-(3-propionate) Dodecyl Sulfate
33. Erythromycin Estorate [jan]
34. Erythromycine Estolate
35. Erythromycin Propionyl Laurylsulfate
36. Erythromycin Propionate, Compd. With Dodecyl Sulfate
37. Unii-xrj2p631hp
38. Einecs 222-532-4
39. Ilosone (tn)
40. Nsc 263364
41. Erythromycin Estolate [usan:usp:ban:jan]
42. Schembl3331
43. Dsstox_cid_17224
44. Dsstox_rid_79309
45. Dsstox_gsid_37224
46. Erythromycin Estolate (usp)
47. Spectrum1501176
48. Chembl2218877
49. Dtxsid1037224
50. Erythromycin, 2'-propionate, Monododecyl Sulfate (salt)
51. Bdbm31688
52. Hms500a11
53. Erythromycin Estolate [mi]
54. Hms1921n13
55. Hms2092j15
56. Pharmakon1600-01501176
57. Erythromycin, Propionate (ester), Compd. With Monododecyl Sulfate
58. Hy-n7121
59. Propionic Acid, 2'-ester With Erythromycin, Dodecyl Sulfate Salt
60. Erythromycin Estolate [usan]
61. Tox21_302229
62. Ccg-38968
63. Erythromycin Estolate [vandf]
64. Lmpk04000015
65. Mfcd00084691
66. Nsc757880
67. S5532
68. Erythromycin Estolate [mart.]
69. Monopropionylerythromycin Laurylsulfate
70. Akos015896121
71. Erythromycin Estolate [usp-rs]
72. Erythromycin Estolate [who-dd]
73. Nsc-757880
74. Sulfuric Acid, Monododecyl Ester, Compd. With Erythromycin 2'-propionate (1:1)
75. Ncgc00180881-01
76. Ncgc00180881-02
77. Ncgc00255571-01
78. Cas-3521-62-8
79. Erythromycin Estolate [orange Book]
80. Erythromycin 2''-propionate Dodecyl Sulfate
81. Erythromycin Estolate [ep Monograph]
82. Propionyl Erythromycin Lauryl Sulfate
83. Cs-0031228
84. Erythromycin Estolate [usp Monograph]
85. Erythromycin Lauryl Sulfate, Propionyl
86. C08031
87. D00851
88. D70256
89. 521e628
90. Sr-05000002085
91. Ilosone Sulfa Component Erythromycin Estolate
92. Q-201066
93. Sr-05000002085-1
94. Q27106503
95. Erythromycin Estolate Component Of Ilosone Sulfa
96. Erythromycin 2'-propionate Dodecyl Sulfate (salt).
97. Erythromycin 2'-propionate Dodecyl Sulphate (salt).
98. Propionic Acid, 2'-ester With Erythromycin, Dodecyl Sulfate
99. Erythromycin, 2'-propanoate, Dodecyl Sulphate (salt)
100. Erythromycin, Propionate (ester), Compd. With Monododecyl Sulfate (1:1)
101. Sulfuric Acid, Monododecyl Ester, Compd. With Erythromycin 2'-propanoate (1:1)
102. (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-4-(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-2-o-propanoyl-beta-d-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione Dodecyl Hydrogen Sulfate
103. [(2s,3r,4s,6r)-4-(dimethylamino)-2-[[(3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] Propanoate;dodecyl Hydrogen Sulfate
| Molecular Weight | 1056.4 g/mol |
|---|---|
| Molecular Formula | C52H97NO18S |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 19 |
| Rotatable Bond Count | 22 |
| Exact Mass | 1055.64263642 g/mol |
| Monoisotopic Mass | 1055.64263642 g/mol |
| Topological Polar Surface Area | 272 Ų |
| Heavy Atom Count | 72 |
| Formal Charge | 0 |
| Complexity | 1550 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 18 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Gastrointestinal Agents
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
96
PharmaCompass offers a list of Erythromycin Estolate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Erythromycin Estolate manufacturer or Erythromycin Estolate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Erythromycin Estolate manufacturer or Erythromycin Estolate supplier.
PharmaCompass also assists you with knowing the Erythromycin Estolate API Price utilized in the formulation of products. Erythromycin Estolate API Price is not always fixed or binding as the Erythromycin Estolate Price is obtained through a variety of data sources. The Erythromycin Estolate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CAS-3521-62-8 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CAS-3521-62-8, including repackagers and relabelers. The FDA regulates CAS-3521-62-8 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CAS-3521-62-8 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CAS-3521-62-8 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CAS-3521-62-8 supplier is an individual or a company that provides CAS-3521-62-8 active pharmaceutical ingredient (API) or CAS-3521-62-8 finished formulations upon request. The CAS-3521-62-8 suppliers may include CAS-3521-62-8 API manufacturers, exporters, distributors and traders.
click here to find a list of CAS-3521-62-8 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CAS-3521-62-8 DMF (Drug Master File) is a document detailing the whole manufacturing process of CAS-3521-62-8 active pharmaceutical ingredient (API) in detail. Different forms of CAS-3521-62-8 DMFs exist exist since differing nations have different regulations, such as CAS-3521-62-8 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CAS-3521-62-8 DMF submitted to regulatory agencies in the US is known as a USDMF. CAS-3521-62-8 USDMF includes data on CAS-3521-62-8's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CAS-3521-62-8 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CAS-3521-62-8 suppliers with USDMF on PharmaCompass.
A CAS-3521-62-8 written confirmation (CAS-3521-62-8 WC) is an official document issued by a regulatory agency to a CAS-3521-62-8 manufacturer, verifying that the manufacturing facility of a CAS-3521-62-8 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CAS-3521-62-8 APIs or CAS-3521-62-8 finished pharmaceutical products to another nation, regulatory agencies frequently require a CAS-3521-62-8 WC (written confirmation) as part of the regulatory process.
click here to find a list of CAS-3521-62-8 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CAS-3521-62-8 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CAS-3521-62-8 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CAS-3521-62-8 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CAS-3521-62-8 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CAS-3521-62-8 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CAS-3521-62-8 suppliers with NDC on PharmaCompass.
CAS-3521-62-8 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CAS-3521-62-8 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CAS-3521-62-8 GMP manufacturer or CAS-3521-62-8 GMP API supplier for your needs.
A CAS-3521-62-8 CoA (Certificate of Analysis) is a formal document that attests to CAS-3521-62-8's compliance with CAS-3521-62-8 specifications and serves as a tool for batch-level quality control.
CAS-3521-62-8 CoA mostly includes findings from lab analyses of a specific batch. For each CAS-3521-62-8 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CAS-3521-62-8 may be tested according to a variety of international standards, such as European Pharmacopoeia (CAS-3521-62-8 EP), CAS-3521-62-8 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CAS-3521-62-8 USP).
